SCHEMBL9256154

SCHEMBL9256154

CCOC(=O)N(C)CCO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.55
CHRNA4 P43681 2/20 0.55
CHRNB4 P30926 1/20 0.55
CHRNA3 P32297 1/20 0.55
ALDH1A1 P00352 3/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
CNR1 P21554 1/20 0.38
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10292049 0.88 ALDH1A1 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL27949079 0.87 CHRNB2 (0.45) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL19997008 0.87 CHRNB2 (0.43) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL254842 0.84 ALDH1A1 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL13479942 0.82 CHRNB2 (0.45) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL995722 0.82 LMNA (0.40) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
Ammonia Solution, Strong SCHEMBL29011843 0.82 ALDH1A1 (0.40) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL11521575 0.82 CHRNB2 (0.65) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL510818 0.81
SCHEMBL21391225 0.80 ALDH1A1 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4272825-A2 MTORC MODULATORS AND USES THEREOF Aeovian Pharmaceuticals, Inc. (US) 2023-11-08 EP disclosed
US-11230557-B2 mTORC modulators and uses thereof AEOVIAN PHARMACEUTICALS, INC. (US) 2022-01-25 US disclosed
US-20210008041-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2021-01-14 US disclosed
WO-2020154447-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. (US) 2020-07-30 WO disclosed
EP-3296300-B1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIV (US) 2019-08-07 EP disclosed
EP-3296300-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER Xavier University (US) 2018-03-21 EP disclosed
EP-3296300-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER Xavier University (US) 2018-03-21 EP disclosed
EP-2822955-B1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIV (US) 2017-07-26 EP disclosed
EP-2822955-B1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIV (US) 2017-07-26 EP disclosed
US-9353132-B2 Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer XAVIER UNIVERSITY OF LOUISIANA (US) 2016-05-31 US disclosed
US-20150080339-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIVERSITY OF LOUISIANA 2015-03-19 US disclosed
US-20150080339-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIVERSITY OF LOUISIANA 2015-03-19 US disclosed
US-20150080339-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIVERSITY OF LOUISIANA 2015-03-19 US disclosed
EP-2822955-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER Xavier University (US) 2015-01-14 EP disclosed
WO-2013134230-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER XAVIER UNIVERSITY (US) 2013-09-12 WO disclosed
WO-2012050263-A1 NOVEL METHOD OF PREPARING ENDOXIFEN CJ CHEILJEDANG CORP. (KR) 2012-04-19 WO disclosed
US-5470851-A Antihistamine, anticoagulants SANKYO COMPANY, LIMITED (JP) 1995-11-28 US disclosed
US-5015640-A Insecticides or miticides CIBA-GEIGY CORPORATION (US) 1991-05-14 US disclosed
US-4874857-A FIBER-REACTIVE DYES BAYER AKTIENGESELLSCHAFT (DE) 1989-10-17 US disclosed
US-4143220-A POLYURETHANES PREPARED WITH NOVEL MANNICH BASES BAYER AKTIENGESELLSCHAFT (DE) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080339-A1 BORON-BASED 4-HYDROXYTAMOXIFEN AND ENDOXIFEN PRODRUGS AS TREATMENT FOR BREAST CANCER ESR1, CYP4F2, DBF4 CHRNB2 3677/4885CHRNA4 3996/4885CHRNB4 2882/4885
US-20210008041-A1 MTORC MODULATORS AND USES THEREOF MTOR, RICTOR, RPTOR CHRNB2 4814/4885CHRNA4 4853/4885CHRNB4 4831/4885
US-11230557-B2 mTORC modulators and uses thereof MTOR, RICTOR, RPTOR CHRNB2 4814/4885CHRNA4 4853/4885CHRNB4 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.